NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Sotera Health Company (SHC) Stock Analysis

Sotera Health Company (SHC) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

SHC

$18.90

−$0.13 (−0.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SHC with… →

SHC Key Statistics

As of Sep 4, 2026
Trading
Open
$18.91
Previous Close
$19.03
Day's Range
18.80–19.05
52-Week Range
13.09–19.85
Volume
1.22M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.78
Valuation
Market Cap
$5.39B
P/E Ratio
33.16
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
17.58
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.43
EPS (ttm)Profit attributable to each share over the last twelve months.
0.57
Financials (FY)
Revenue (FY)
$1.16B+5.74%
Net Income (FY)
$77.95M+75.57%
Profit marginThe share of revenue left as profit after all costs and taxes.
13.44%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
285.37M
1-Year Return
+21.94%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
2.78M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SHC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.14%
2025+28.95%
2024−18.81%
2023+102.28%
2022−64.63%
2021−14.18%
2020 (partial year)+9.32%

As of September 4, 2026.

SHC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.16B$77.95M6.7%
2024$1.10B$44.40M4.0%
2023$1.05B$51.38M4.9%
2022$1.00B−$233.57M−23.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.16B$645.53M$362.03M$77.95M6.7%
2024$1.10B$602.30M$297.63M$44.40M4.0%
2023$1.05B$577.16M$276.69M$51.38M4.9%
2022$1.00B$557.00M$248.35M−$233.57M−23.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SHC Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricSHCDiagnostics & Research medianvs median
P/E33.1633.080% above
P/S ratio4.434.9911% below
Profit margin13.44%0.00%13.4 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sotera Health Company (SHC) is capitalised at $5.39B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 3,000 employees.

SHC last closed at $18.90 on September 4, 2026. That is −$0.13 (−0.68%) against the previous close. The 52-week range on file runs from $13.09 to $19.85. The latest close sits 44.39% above that 52-week low.

Financial Health

In fiscal 2025, Sotera Health Company reported revenue of $1.16B. That is +5.74% against the prior fiscal year, when revenue was $1.10B. The same year closed with net income of $77.95M. That is +75.57% against the prior fiscal year. The reported profit margin is 13.44%. That is 13.4 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 0.57.

Across the 4 fiscal years on file, revenue moves from $1.00B in 2022 to $1.16B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

SHC trades at a trailing price-to-earnings ratio of 33.16. That is 0.24% above the Diagnostics & Research median of 33.08. On forward earnings the ratio is 17.58. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.31. The price-to-sales ratio is 4.43. On price-to-sales that is 11.13% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 1.78. Annualized volatility over the trailing 5 years is 64.83%. Over the trailing twelve months the price has returned +21.94%. Across 5 years the annualized return works out at −6.09%.

Growth & Income

The record shows no dividend for SHC.

2026 is still running; the price is +7.14% year to date. Across the complete calendar years on file, 2023 returned +102.28% and 2022 returned −64.63%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Sotera Health Company (SHC) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sotera Health Company SHC $5.39B 33.2
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Sotera Health Company trades at a P/E of 33.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sotera Health Company

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Visit website →